Helixxa Certified to Provide NimbleGen Array Services in Brazil

(PresseBox) (Madison, WI, USA, ) Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) is pleased to announce that São Paulo-based genomic services provider Helixxa has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. Helixxa has been certified to process customer samples for NimbleGen Gene Expression arrays in their lab outside of São Paulo. Helixxa is the first and only genomics service provider in Latin America, as well the only provider in the region that offers multiple Roche Applied Science products including: 454 Genome Sequencer FLX, MagNA Pure, LightCycler®, and MagNA Lyser. Helixxa's team of experts are experienced at performing high-quality services for many different customer segments, which include academic research, medical research, agri-business, and pharmaceutical and consumer goods industries.

"We are extremely grateful and excited for this partnership with Roche NimbleGen. Our commitment to excellence and the expertise of our team will provide the LATAM life science market with the genomic tools and knowledge to further research in this exciting, emerging market. We are extremely excited to offer the NimbleGen Gene Expression and CGH arrays to the Brazilian and Latin American market as we believe they provide the most comprehensive and robust solution for life sciences applications" said Mario Antonio de Oliveira Jr., CEO at Helixxa.

"Roche NimbleGen is extremely excited to welcome Helixxa as our first certified service provider in Latin America for gene expression and comparative genome hybridization applications. This partnership with Helixxa represents a significant step forward positioning Roche NimbleGen for aggressive expansion into the rapidly growing genomics market in Brazil and Latin America" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

About Helixxa

Helixxa is located in Campinas, within the state of São Paulo and is Brazil's first genomic service provider. Throughout the world, genomics has been a priority with large government and multinational investments and has been showing great profitability in several countries. Helixxa is fundamental in these efforts, whereby they supply and partner for providing genomic service solutions with key industrial markets, academic research, and health proposals. Helixxa specializes in providing services (sequencing, SNPs and genotyping analysis, DNA and RNA analysis, complete genomes, etc.) for furthering our understanding of diseases and predispositions in humans, animals, plants and other living organisms. Helixxa provides large-scale and high throughput analysis, with complete and reliable information (bioinformatics inclusive), ensuring transparency and simplicity on the understanding of information. Visit www.helixxa.com for more information.

For life science research only. Not for use in diagnostic procedures.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.


Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.